Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 63Lymphoma, Mantle-Cell 39Waldenstrom Macroglobulinemia 18Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Follicular 14Recurrence 10Lymphoma, B-Cell, Marginal Zone 10Leukemia 9Lymphoma, B-Cell 8Lymphoma 8Neoplasms 7Lymphoma, Non-Hodgkin 5Leukemia, Prolymphocytic 4Hodgkin Disease 4Multiple Myeloma 3Leukemia, Myeloid, Acute 3Leukemia, B-Cell 3Hematologic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Plasma Cell 2Glioblastoma 2Chromosome 17 deletion 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Bronchiolitis Obliterans Syndrome 2Brain Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Prostatic Neoplasms 1Primary Central Nervous System Lymphoma (PCNSL) 1

Interventions

pembrolizumab 1ibrutinib 1Watchful Waiting 1Sertraline 1Quality of Life 1Electrocardiography 1Clinical Laboratory Techniques 1Bone Marrow Transplantation 1Bone Marrow Examination 1Biopsy 1Azacitidine 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Bone Marrow Diseases × ibrutinib × Clear all
NCT03514017 2026-03-02

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
5 enrolled 11 charts
LymphoidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡